Test Details: This testing, consisting of FLT3, NPM-1 and C-KIT mutations, is recommended in the NCCN guidelines for determination of AML risk status in patients with cytogenetically normal AML. Mutations in NPM1 gene is a predictor of favourable prognosis and good response to induction chemotherapy. The presence of (FLT3) internal tandem duplication is associated with short disease-free survival. The mutations in exon 11 of the proto-oncogene c-Kit might play an important role in the pathogenesis and represent useful predictive genetic marker in AML.